Vyvgart® Hytrulo (efgartigimod alfa/hyaluronidase-qvfc) – New orphan drug approval
June 20, 2023 - Argenx announced the FDA approval of Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase-qvfc), for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
Top